Effectiveness of statins in Medicare-eligible patients and patients > 65 years using clinical practice data

Abstract

Objective: This study compared effectiveness of rosuvastatin (RSV) with other statins on lowering LDL-C and LDL-C goal attainment among Medicare-eligible patients (age ≥ 65 years) and patients with age < 65 years treated in usual clinical practice to provide evidence of real-world effectiveness of statins. Methods: Retrospective cohort study was conducted in patients, newly prescribed statin therapy during August 2003 to May 2005. Patient inclusion criteria: no prior prescription for dyslipidaemic medication in the preceding 12 months, continuously enrolled for ≥ 15 months and ≥ 90-day supply of statin. Effectiveness of RSV in reducing LDL-C and attaining LDL-C goal when compared with other statins was evaluated using multivariate regression, adjusting for baseline LDL-C, age, gender, smoking, hypertension, coronary heart disease (CHD), systolic blood pressure and therapy duration. Results: Adjusted per cent LDL-C reduction was significantly greater (p < 0.05) with RSV (24.3% for ≥ 65 and 28.5% for < 65) compared with ATV (17.5%, 21.3%), SMV (14.8%, 18.4%), PRV (11.3%, 15.8%), FLV (10.7%, 20.6%) and LOV (13.3%, 14.4%). Among patients in both age groups at high or moderate CHD risk, a greater proportion of RSV patients attained LDL-C goal (76.0% for age group ≥ 65 years and 78.4% for age group < 65 years) vs. 50.5-73.0% for ≥ 65 and 51.3-71.5% for < 65 years of age on other statins (p < 0.0001). Conclusions: Rosuvastatin is more effective in lowering LDL-C in Medicare-eligible patients and patients < 65 years of age when compared with other statins in usual clinical practice. Moreover, RSV patients had higher LDL-C goal attainment rates when compared with other statins in high- and moderate-risk patients. The study results have implications for clinicians in selecting the optimal statin to meet individual patient care needs. © 2007 Astrazeneca Pharmaceuticals LP.